Abstract

Simple SummaryImmune cells are increasingly used for therapy in cancer and other diseases. To better understand immune-cell kinetics, cell-tracking with highly sensitive imaging modalities is required. The aim of this study was to develop a new strategy for the in vivo tracking of a small number of cells, using positron emission tomography (PET). We labeled poly(lactic-co-glycolic acid) nanoparticles containing a primary endcap (PLGA-NH2) with the radionuclide zirconium-89. The nanoparticles were characterized for size, polydispersity index, zetapotential and radiolabel retention. Subsequently, they were used for the ex vivo radiolabeling of a monocyte cell line (THP-1). We demonstrated that these radiolabeled monocyte cells can be traced in vivo in mouse tumor and infection models.The exponential growth of research on cell-based therapy is in major need of reliable and sensitive tracking of a small number of therapeutic cells to improve our understanding of the in vivo cell-targeting properties. 111In-labeled poly(lactic-co-glycolic acid) with a primary amine endcap nanoparticles ([111In]In-PLGA-NH2 NPs) were previously used for cell labeling and in vivo tracking, using SPECT/CT imaging. However, to detect a low number of cells, a higher sensitivity of PET is preferred. Therefore, we developed 89Zr-labeled NPs for ex vivo cell labeling and in vivo cell tracking, using PET/MRI. We intrinsically and efficiently labeled PLGA-NH2 NPs with [89Zr]ZrCl4. In vitro, [89Zr]Zr-PLGA-NH2 NPs retained the radionuclide over a period of 2 weeks in PBS and human serum. THP-1 (human monocyte cell line) cells could be labeled with the NPs and retained the radionuclide over a period of 2 days, with no negative effect on cell viability (specific activity 279 ± 10 kBq/106 cells). PET/MRI imaging could detect low numbers of [89Zr]Zr-THP-1 cells (10,000 and 100,000 cells) injected subcutaneously in Matrigel. Last, in vivo tracking of the [89Zr]Zr-THP-1 cells upon intravenous injection showed specific accumulation in local intramuscular Staphylococcus aureus infection and infiltration into MDA-MB-231 tumors. In conclusion, we showed that [89Zr]Zr-PLGA-NH2 NPs can be used for immune-cell labeling and subsequent in vivo tracking of a small number of cells in different disease models.

Highlights

  • Cell-based therapy is maturing into clinical practice and holds great promise for treating cancer, as well as immune-related diseases

  • T cells can be labeled with highly derivatized crosslinked iron oxide nanoparticles (NPs) and detected with magnetic resonance imaging (MRI) [10]

  • Positron emission tomography (PET) is commonly applied in clinical practice for diagnosis, staging and response monitoring in cancer and other diseases

Read more

Summary

Introduction

Cell-based therapy is maturing into clinical practice and holds great promise for treating cancer, as well as immune-related diseases. In vivo cell tracking is desired to better understand the complex cell targeting mechanism and cell–cell interactions Such tools could guide the development of treatment strategies to increase tumor-targeting and minimize off-target accumulation and associated toxicity [1,2,3,4]. In clinical settings, [111In]In-oxine and [99mTc]Tc-HMPAO are used in combination with single-photon emission computed tomography (SPECT) imaging [16,17]. This labeling strategy is fast and results in a good labeling efficiency, it has several drawbacks. We introduced the radiometal zirconium-89 (89Zr) as a positron emitter, with an ideal half-life (78.41 h) for cell tracking

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call